Epilepsy surgery is not the only answer for drug-resistant epilepsy, and it is not always an option. Some seizure foci sit inside eloquent brain regions that cannot be surgically approached. Others arise from multiple locations simultaneously. Some patients are not surgical candidates for medical reasons. For these individuals, the treatment landscape has changed considerably in the past three years. New-generation anti-seizure medications with genuinely different mechanisms of action, more intelligent neurostimulation devices that respond to the brain in real time, and dietary protocols with stronger evidence than many medications now offer meaningful seizure control where older approaches had failed. This guide maps all three categories of advance, with the specific data that matters, and explains how international patients access these options through India's best neurologists.
Why Epilepsy Treatment Without Surgery Has Advanced So Significantly
Approximately one-third of people with epilepsy develop drug-resistant epilepsy, defined as ongoing seizures despite adequate trials of at least two appropriate anti-seizure medications. For decades, the options beyond medication were limited to surgery or watchful management. Three factors have changed this:
- New medications with distinct dual mechanisms that address neuronal excitability and inhibition simultaneously
- Smarter neurostimulation devices, particularly closed-loop systems that respond to brain activity in real time
- Clearer dietary therapy evidence, with four validated dietary protocols and specific data on seizure reduction rates
Together, these advances mean that epilepsy treatment without surgery now has more tools than at any previous point in the condition's clinical history.
Advance 1: New-Generation Anti-Seizure Medications
Cenobamate
Cenobamate is the most clinically significant new anti-seizure medication approved in the past five years. It has two distinct mechanisms of action: it inhibits persistent sodium current in neurons, reducing excessive firing, while simultaneously enhancing inhibition through GABA-A receptors via a non-benzodiazepine site. This dual mechanism gives it an anti-seizure profile unlike any previously available medication.
Key data points:
-
FDA-approved for focal seizures in adults; also approved by the European Medicines Agency
-
In randomised controlled trials, adjunctive cenobamate achieved 21 percent seizure freedom in patients with focal epilepsy
-
In seven observational studies covering 223 patients, responder rates of 50 to 85 percent were recorded
-
The FDA approved new administration routes for cenobamate in mid-2025, expanding flexibility for patients with swallowing difficulties
-
In real-world Italian epilepsy centre data, 91 percent of patients completed the 10.7-month efficacy analysis, with meaningful seizure reduction and an acceptable adverse effect profile
Cenobamate is available in India's leading epilepsy centres as part of the newer-generation ASM formulary, offering patients with drug-resistant focal epilepsy a genuinely new pharmacological option after older agents have failed.
Ganaxolone
Ganaxolone is an FDA-approved neurosteroid that modulates GABA-A receptors through a different mechanism than benzodiazepines, making it effective in patient groups with high benzodiazepine tolerance. It has a specific FDA indication for CDKL5 deficiency disorder, a rare genetic epilepsy, and is being studied for broader use in drug-resistant generalised epilepsies.
In a phase 3 randomised trial, ganaxolone achieved a 28.2 percent reduction in drop seizures versus placebo in CDKL5 deficiency phenotypes. For patients with Lennox-Gastaut syndrome, a September 2025 comprehensive narrative review confirmed ganaxolone's efficacy in LGS-like CDKL5 phenotypes.
Fenfluramine
Fenfluramine received FDA approval for Dravet syndrome seizures, a severe childhood-onset genetic epilepsy previously resistant to most treatments. Its mechanism involves both serotonergic and sigma-1 receptor pathways that reduce seizure frequency independent of sodium channel blockade. Clinical trials in Dravet syndrome show 50 to 70 percent responder rates, with a meaningful proportion achieving greater than 75 percent reduction in convulsive seizures.
What the 2025 ASM Update Confirms
The Continuum Neurology 2025 Update on Antiseizure Medications (February 2025) confirms that one new ASM, ganaxolone, received FDA approval in this cycle, and that indications for previously approved medications including cenobamate and fenfluramine were expanded. The update also highlights the growing evidence base for cannabidiol (Epidiolex) across Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex-related epilepsy.
| Medication | Key Indication | Mechanism | Notable Data |
|---|---|---|---|
| Cenobamate | Drug-resistant focal epilepsy | Dual: Na+ channel + GABA-A | 21% seizure freedom in RCT; 50-85% responder rates |
| Ganaxolone | CDKL5 deficiency disorder | Neurosteroid GABA-A modulation | 28.2% drop seizure reduction vs placebo |
| Fenfluramine | Dravet syndrome | Serotonergic + sigma-1 receptor | 50-70% responder rate in trials |
| Cannabidiol (Epidiolex) | Dravet, LGS, TSC epilepsy | Non-THC cannabinoid | FDA-approved; 39-43% responder rates in LGS RCT |
| Perampanel | Focal and generalised epilepsy | AMPA receptor antagonist | 26-69% responder rates in LGS studies |
Advance 2: Neurostimulation Without Open Brain Surgery
Neurostimulation for epilepsy treatment without surgery has moved beyond vagus nerve stimulation into a generation of smarter, more targeted devices, alongside genuinely non-invasive options that require no implant at all.
Vagus Nerve Stimulation (VNS)
The original neurostimulation therapy for epilepsy, VNS involves a small generator implanted under the skin of the chest with a lead connecting to the left vagus nerve in the neck. It is not brain surgery. Regular electrical impulses delivered to the vagus nerve reduce seizure frequency in approximately 50 percent of patients, with ongoing improvement over two to three years of use.
-
Reduces seizure frequency by 50% or more in about half of patients
-
Approved for drug-resistant epilepsy patients aged four and above
-
Responsive versions (AutoStim) that detect heart rate increases during seizures and deliver immediate stimulation are now the standard implant
Responsive Neurostimulation (RNS)
RNS is the most sophisticated closed-loop neurostimulation system currently available. A small generator is implanted in the skull, and electrodes are placed directly at the seizure focus or foci within the brain. The device continuously monitors brain electrical activity and when it detects abnormal patterns consistent with seizure onset, it immediately delivers a small electrical pulse to interrupt the abnormal activity before a clinical seizure develops.
Key advantages:
-
Personalised to the individual's seizure onset pattern through AI-driven learning over time
-
The device records brain activity 24 hours a day, providing data for programming optimisation at follow-up
-
Approved for adults with drug-resistant partial onset epilepsy with one or two seizure foci
-
Three to five-year responder rates of 55 to 65 percent in major trial data
Deep Brain Stimulation (DBS) for Epilepsy
Deep Brain Stimulation (DBS) for epilepsy targets the anterior nucleus of the thalamus, a hub in the network that propagates seizures. The SANTE trial demonstrated that bilateral anterior thalamic DBS reduced median seizure frequency by 41 percent at one year and by 69 percent at five years, with 68 percent of patients experiencing at least 50 percent seizure reduction at five years.
DBS for epilepsy is now available at select centres in India, including leading NABH and JCI-accredited hospitals, at costs 60 to 80 percent lower than in the USA or UK.
Non-Invasive Neurostimulation: Four Emerging Options
For patients who prefer no implanted device, four non-invasive modalities are available or in advanced development:
-
Transcutaneous VNS (tVNS): Delivers vagus nerve stimulation through a skin electrode at the ear, with no surgical implant required. CE-marked for epilepsy in Europe.
-
Trigeminal nerve stimulation (TNS): External stimulation of the trigeminal nerve via forehead electrodes, targeting the same neural circuits as VNS but entirely non-invasively.
-
Repetitive transcranial magnetic stimulation (rTMS): Focused magnetic pulses delivered to the seizure focus through the scalp, reducing cortical excitability without any implant.
-
Focused ultrasound: Emerging, with clinical trials active. High-intensity focused ultrasound can modulate or ablate epileptogenic tissue without incision, guided by real-time MRI.
Advance 3: Dietary Therapies With Stronger Evidence Than Many Medications
Dietary therapy achieves 50 percent or higher seizure reduction in more than half of drug-resistant epilepsy patients in the short term, compared with care as usual. This figure, from a 2025 Baptist Health clinical review, matches or exceeds the responder rates of several recently approved anti-seizure medications.
Four dietary protocols are validated for epilepsy treatment without surgery:
| Diet | Carbohydrate Restriction | Fat Content | Best Evidence For |
|---|---|---|---|
| Classic Ketogenic Diet | Very strict (4:1 ratio) | Very high | Drug-resistant childhood epilepsy |
| Medium-Chain Triglyceride Diet (MCTD) | Moderate | High (MCT focus) | Better tolerability, similar efficacy to classic KD |
| Modified Atkins Diet (MAD) | Less strict | High | Adolescents and adults; easier adherence |
| Low-Glycemic Index Treatment (LGIT) | Moderate (glycaemic control) | Moderate | Older children and adults; less restrictive |
The mechanism is multifactorial. Ketogenic diets elevate inhibitory neurotransmitters, reduce neuronal excitability, increase brain energy production via ketone bodies, and reduce proinflammatory factors. Recent research has also identified effects on the gut microbiota through the gut-brain axis as a contributing mechanism. Dietary therapy is initiated under medical supervision, not self-administered, and requires specific nutritional monitoring to avoid deficiency and manage adverse effects.
How India's Best Neurologists Deliver These Options
International patients choose India for epilepsy treatment without surgery because India's leading epilepsy centres provide the complete range: new ASM prescribing including cenobamate and cannabidiol where indicated, VNS and RNS device implantation, DBS for refractory epilepsy, dietary therapy initiation under expert dietitian and epileptologist supervision, and non-invasive neurostimulation programmes.
The best neurologists in India managing drug-resistant epilepsy work within fully integrated epilepsy programmes at NABH and JCI-accredited hospitals where all of these options are coordinated by a multidisciplinary team including epileptologists, neuropsychologists, dietitians, and neurostimulation device specialists. This integrated model is not universally available in many of the countries from which international patients travel, and accessing it in India costs 60 to 80 percent less than equivalent treatment in the USA or UK.
VNS implantation in India costs approximately Rs. 3,50,000 to Rs. 5,50,000 (USD 4,200 to USD 6,600). RNS system implantation, where available, costs significantly more but remains substantially below Western pricing. Dietary therapy evaluation and initiation costs a fraction of what the same process would require in a private USA or UK epilepsy centre.
How Karetrip Connects International Patients to Advanced Epilepsy Care in India
Whether a patient needs a specialist review of their current medication regimen for cenobamate suitability, an evaluation for VNS or RNS implantation, or initiation of a supervised dietary therapy programme under an epileptologist, Karetrip identifies the most appropriate epilepsy centre in India and coordinates the full patient journey. Every referral is based on a review of the patient's existing records and investigation history, ensuring the team proposed has specific experience in the treatment pathway being considered.
Chat with our Medical care assistant, RUA, for quick guidance and support and take the first step toward accessing the latest epilepsy treatment without surgery through India's leading epilepsy specialists.